Daniel Zandberg

20PUBLICATIONS

141CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsOther biomedical and clinical sciences not elsewhere classifiedChemotherapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|May 08, 2026

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Apr 01, 2026

Systemic Treatment of Thyroid Cancer: ASCO Guideline.

Nabil F Saba, Nofisat Ismaila, Douglas Adkins

|Mar 13, 2026

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Aarti Bhatia, Zhengjia Chen, Yuji Zhang

|Jan 16, 2026

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

Martina Chirra, Andrew Elliott, Hira Shaikh

|Dec 04, 2025

Reply to: Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials.

Robert L Ferris, Julie E Bauman, Hong Wang

|Nov 03, 2025

Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.

Seka Lazare, Zhuosheng Gu, Noah Earland

Pageof 4

Frequent Collaborators

Robert L Ferris

Nabil F Saba

Mark W Kubik

Nassim Morsli

Jill Walker

Weimin Li

Nicholas Holoweckyj

Rajiv Raja

Sophie Wildsmith

James P Ohr

Frequent Collaborators

Robert L Ferris

Nabil F Saba

Mark W Kubik

Nassim Morsli